KAI-11101

• Description :

  KAI-11101 is the inhibitor for dual leucine zipper kinase (DLK, MAP3K12) with a Ki of 0.7 nM. KAI-11101 inhibits Paclitaxel (HY-B0015) -induced cJun phosphorylation (IC50=95 nM) and thus inhibits the activation of MAPK pathway. KAI-11101 is blood brain barrier penetrable and can be further investigated for its neuroprotective property[1].

• UNSPSC :

  12352005

• Target :

  MAP3K; p38 MAPK

• Related Pathways :

  MAPK/ERK Pathway

• Field of Research :

  Neurological Disease

• Smiles :

  O=C1C(N(CC)N=C2C3=CC(OC(F)F)=C(N)N=C3)=C2C=CN1[C@H]4[C@@H](OC)CC(F)(F)CC4

• Molecular Formula :

  C21H23F4N5O3

• Molecular Weight :

  469.43

• References & Citations :

  [1]Lagiakos HR, et al., In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury. J Med Chem. 2024 Dec 13.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported